OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancers, such as ovarian and certain thyroid cancers. The Company’s major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumors. OXiGENE is dedicated to leveraging its scientific expertise, intellectual property and therapeutic development capabilities to bring life-extending and life-enhancing medicines to patients.
Welcome From Our New CEO
Dr. Chaplin is a prominent tumor biologist who pioneered early work related to vascular disrupting agents.
- OXiGENE Announces Third Quarter 2014 Earnings Conference Call and Webcast
- OXiGENE Announces First Patient Enrolled in Phase 1b/2 Study of Fosbretabulin Combined With Pazopanib in Patients With Advanced Recurrent Ovarian Cancer
- OXiGENE Announces Presentation of Data from the Phase 2 GOG186I Study at the 15th Biennial Meeting of the International Gynecologic Cancer Society
After many years of research, we believe that Fosbretabulin is poised to become the first commercialized VDA, having shown meaningful clinical activity and tolerability in clinical trials to date.
Vascular Disrupting Agents or “VDAs” block blood flow through established tumor blood vessels, thereby starving tumors of oxygen and essential nutrients, leading to tumor cell death.